New stem cell combo could boost survival in blood cancer patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 14 and 60 years, with no gender restriction. * Intermediate- or high-risk AML in first complete remission (CR1). * AML in second or subsequent complete remission (≥ CR2). * Relapsed or refractory AML. * Low-risk AML meeting any of the following: Failure to achieve a ≥3-log reduction in RUNX1::RUNX1T1 transcript level compared with baseline after 2 consolidation cycles, or loss of major molecular remission (MMR) within 6 months; CBFB::MYH11/ABL ratio \> 0.1% at any time point after 2 consolidation cycles in patients with CBFB::MYH11-rearranged AML; Presence of D816 KIT mutation in patients with CBFB::MYH11-rearranged AML; Flow cytometry-positive MRD at any time point after 2 consolidation cycles in patients with CEBPA double-mutant AML; Persistently positive MRD after chemotherapy in patients with NPM1-mutated AML. * Intermediate-2 or high-risk MDS according to the IPSS scoring system. * Adequate general health status and ability to tolerate hematopoietic stem cell transplantation. * Provision of signed informed consent and willingness to comply with study-required follow-up and examinations. Exclusion Criteria: * Prior history of other hematopoietic stem cell transplantation. * History of ex vivo T-cell-depleted stem cell transplantation. * Survival duration of less than 1 month after transplantation. * Severe organ dysfunction, including significant impairment of hepatic, renal, cardiac, or pulmonary function. * Active severe infection, such as uncontrolled pneumonia, sepsis, or other systemic infections. * History of severe hypersensitivity reactions to study medications, including cyclophosphamide or anti-thymocyte globulin (ATG). * Presence of severe psychiatric disorders or cognitive impairment that precludes compliance with study treatment and follow-up. * Pregnant or lactating women. * Concurrent malignancy of other organ system. * Any other medical conditions deemed inappropriate for study participation by the treating investigators.